NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth. “2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president…







